Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Stoke Therapeutics, Inc. (STOK : NSDQ)
 
 • Company Description   
Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford, Massachusetts.

Number of Employees: 170

 
 • Price / Volume Information   
Yesterday's Closing Price: $25.68 Daily Weekly Monthly
20 Day Moving Average: 1,130,522 shares
Shares Outstanding: 64.53 (millions)
Market Capitalization: $1,657.03 (millions)
Beta: 1.26
52 Week High: $40.22
52 Week Low: $20.32
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -1.65% -2.30%
12 Week -12.89% -17.84%
Year To Date -19.09% -28.60%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
45 WIGGINS AVENUE
-
BEDFORD,MA 01730
USA		 ph: 781-430-8200
fax: -		 ir@stoketherapeutics.com http://www.stoketherapeutics.com
 
 • General Corporate Information   
Officers
Ian F. Smith - Chief Executive Officer and Director
Arthur O. Tzianabos - Chairman of the Board of Directors
Thomas E. Leggett - Chief Financial Officer
Julie A. Smith - Director
Seth L. Harrison - Director

Peer Information
Stoke Therapeutics, Inc. (CORR.)
Stoke Therapeutics, Inc. (RSPI)
Stoke Therapeutics, Inc. (CGXP)
Stoke Therapeutics, Inc. (BGEN)
Stoke Therapeutics, Inc. (GTBP)
Stoke Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 86150R107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/03/26
Share - Related Items
Shares Outstanding: 64.53
Most Recent Split Date: (:1)
Beta: 1.26
Market Capitalization: $1,657.03 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.93 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.52 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/03/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.80
Price/Cash Flow: -
Price / Sales: 60.06
EPS Growth
vs. Year Ago Period: -132.50%
vs. Previous Quarter: -17.72%
Sales Growth
vs. Year Ago Period: -32.51%
vs. Previous Quarter: 49.70%
ROE
09/30/26 - -
06/30/26 - -59.36
03/31/26 - -48.84
ROA
09/30/26 - -
06/30/26 - -51.46
03/31/26 - -42.27
Current Ratio
09/30/26 - -
06/30/26 - 7.69
03/31/26 - 8.99
Quick Ratio
09/30/26 - -
06/30/26 - 7.69
03/31/26 - 8.99
Operating Margin
09/30/26 - -
06/30/26 - -753.60
03/31/26 - -529.20
Net Margin
09/30/26 - -
06/30/26 - -753.60
03/31/26 - -529.20
Pre-Tax Margin
09/30/26 - -
06/30/26 - -758.23
03/31/26 - -533.18
Book Value
09/30/26 - -
06/30/26 - 5.36
03/31/26 - 6.34
Inventory Turnover
09/30/26 - -
06/30/26 - -
03/31/26 - -
Debt-to-Equity
09/30/26 - -
06/30/26 - 0.00
03/31/26 - 0.00
Debt-to-Capital
09/30/26 - -
06/30/26 - 0.00
03/31/26 - 0.00
 

Powered by Zacks Investment Research ©